The clinical efficacy of small intravenous boluses of insulin in treating diabetic decompensation was tested in 23 patients presenting in either a ketoacidotic or a nonketotic diabetic coma. In addition to the usual ionic and fluid replacement, the patients received hourly intravenous injections of insulin 5 IU. This dose lowered blood glucose levels in all but two patients. In the patients who responded the percentage decrease in glycaemia was similar whatever the initial glucose concentration and averaged (± SE of mean) 50-± 300 in five hours. Close monitoring of insulin and glucose concentrations after intravenous insulin in three patients showed that despite the short half life of insulin the effect of the intravenous bolus lasted for about 60 minutes. The overall clinical effectiveness of this type of treatment is comparable to that of the other low-dose regimens. Owing to its simplicity, this technique of insulin administration seems most suitable for the routine treatment of diabetic coma.
Introduction
Recently the use of large doses of insulin for treating diabetic coma has been questioned. A regimen of hourly intramuscular injections of [5] [6] [7] [8] [9] [10] IU has proved to be as effective in lowering blood glucose and ketone concentrations as conventional treatment with large doses.1 'This treatment, although modified, has also been successfully used in children.3 Similarly, good results have been obtained with continuous intravenous infusions of 1-12 IU/hour,4 but infusions require special equipment that is not available in all hospitals.3
These low-dose treatments are based on the knowledge that the optimum level of plasma insulin to promote glucose transport is small, lying between 20 and 200 mU/1.8 The use of repeated small intravenous boluses has been rejected1 4 7on the basis of the very short plasma half life of insulin (about four to five minutes).9 These theoretical objections against intermittent intravenous insulin treatment were not confirmed in a preliminary clinical study, which showed it to be as effective as the other low-dose regimens. 10 This study analyses the clinical efficacy of small intravenous insulin boluses in the treatment 
Patients and methods
Twenty-three consecutive patients with severe uncontrolled diabetes were studied. All had plasma glucose levels above 19 4 mmol/l (350 mg/100 ml), and all required immediate intravenous fluid and insulin. Nineteen patients were in ketoacidosis and four presented with a hyperosmolar non-ketotic decompensation. Six patients had never been treated with insulin. Six presented clinical evidence of infection and three others had signs of cardiac failure. One patient was in overt shock on admission, with a rectal temperature of 33°C. Initial plasma glucose levels ranged from 20 0 to 96-0 mmol/l (360-1730 mg/100 ml) (mean±SE of mean: 44 5+4 4 mmol/l (801±80 mg/100 ml)). Arterial blood pH ranged from 6-75-7 40 (mean: 7 09±0-037) and serum potassium from 2 1-8 3 mmol (mEq)/l (mean: 5-3 ±0t4 mmol/l).
In the eight ketoacidotic patients in whom it was determined Phydroxybutyrate ranged from 3-29 to 15 14 mmol/l (34-2-158 mg/100 ml) (mean: 9-37±1 28 mmol/l (97-5±13 3 mg/100 ml)), free fatty acids from 0 77 to 2-74 mmol/l (mean: 1-77+0-28 mmol/l), and glycerol from 0-32 to 1-16 mmol/l (2 9-10-7 mg/100 ml) (mean: 0-40±0-14 mmol/l (3-7+1-3 mg/100 ml)).
During treatment plasma glucose was measured every hour and serum electrolytes every two hours. Plasma immunoreactive insulin was assayed according to the method of Herbert et al," and plasma i-hydroxybutyrate was determined enzymatically."2 All patients were treated with insulin and intravenous fluids. Insulin-Whatever the biochemical values on admission, 5 IU of insulin was given intravenously every hour as a single bolus with no initial loading dose. Once the blood sugar level had reached 13 9 mmol/l (250 mg/100 ml) the intravenous insulin boluses were stopped and insulin was administered subcutaneously every six hours according to glycosuria, with an initial dose of 10 IU.
Intravenous fluids and electrolytes-Physiological saline (0 154-M) was given at the rate of 1 litre in 60 minutes then 500-750 ml per hour; when plasma glucose had fallen below 13-9 mmolil saline was replaced by dextrose (50 g/l). When the initial arterial blood pH was less than 7 10, 500-1000 ml sodium bicarbonate (0 166-M) was given instead of saline during the first hour of treatment. Potassium chloride 40 mmol per litre of replacement fluid was started as soon as serum potassium levels were under 5 mmol/l.
Results
Glucose-The individual plasma glucose responses to treatment are shown in fig 1. The mean rate of fall calculated over the whole period of decreasing glucose concentration was 4 3 mmol/l/hour (77 mg/100 ml/hour). The percentage fall from initial values tended to be similar whatever the initial glucose level and averaged 50 +30% in five hours.
Glucose response was apparently unrelated to the severity of acidosis or history of insulin treatment. Only two patients did not respond adequately to treatment with 5 IU/hour. One was in severe shock, with anuria and hypothermia (33'C) on admission. The fall in plasma glucose level was unusually low (28% in five hours; (case 1, fig 1B) , and the dose of 5 IU/hour was certainly of borderline efficacy. Clinical recovery, however, was excellent. Presumably a dose of 10 IU/hour would have been better. A second patient (case 2) did not respond at all to 5 IU/hour. In addition to her diabetic decompensation, she was severely ill with bacterial endocarditis, cardiac and renal failure, and obesity. She was obviously insulin-resistant before the acute episode since decompensation developed while she was treated with 120 IU/day. Insulin 20 IU/hour was needed to obtain an adequate glucose response.
Ketone bodies--Hydroxybutyrate concentrations fell steadily from an average admission value of 9-37 mmol/l (97-5 mg/100 ml) (in eight patients) (fig 2) . Some patients were still fairly ketotic when their hyperglycaemia was controlled (glucose level < 13-9 mmol/l).
Effect of insulin injections on plasma insulin and glucose concentrations-To define precisely the pattern of plasma insulin and glucose changes during treatment we determined the concentration of these ) . This disadvantage seems merely theoretical, however, and it is unlikely that it might be harmful. Good clinical results were obtained in our series of 23 patients: mortality was low and not directly related to the diabetic decompensation; the percentage fall in glycaemia with time was remarkably similar in most patients whatever the degree of initial hyperglycaemia or acidosis (50±30 in five hours), and the pattern of glycaemic response can therefore be easily predicted for any given patient at the start of the treatment. Interestingly, the slower rates of decrease in glucose concentration were observed in three patients with cardiac failure who could not receive large amounts of fluid. This re-emphasises the fact that early and vigorous fluid replacement remains an essential part of the treatment of diabetic coma whatever the insulin regimen used. Hyperketonaemia took longer to correct than hyperglycaemia and several patients were still ketotic when glycaemia had returned to a level of about 13-9 mmol/l (fig 2) . Similar observations were made by Soler et al"3 irrespective of the mode of administration and the amount of insulin given to the patient. Finally, none of our patients showed late hypoglycaemia or hypokalemia.
The dose of 5 IU/hour was effective in all but two cases: in one patient the decrease in plasma glucose was unusually low, and in the other injections of 20 IU/hour were needed to obtain a significant hypoglycaemic action. This resistance to insulin was probably related to the severity of the clinical state; the first patient was in deep coma with severe dehydration, hypovolaemic shock, and hypothermia, and the second one presented bacterial endocarditis with multiple cerebral infarctions, and cardiac and renal failure. In the second patient relative insulin resistance existed before the acute episode since decompensation developed while she was treated with 120 IU/day. Thus some patients may be refractory to these low-dose insulin regimens.
In conclusion, our results indicate that hourly intravenous boluses are a convenient and efficient way of administering insulin in the treatment of diabetic coma. The hormone can easily be injected through the tubing used for the fluid replacement. This mode of administration is much simpler than the constant infusion technique; even small hospitals with reduced medical staff should be able to apply this technique routinely. If, under careful monitoring, resistance to the standard dose of 5 IU/hour occurs the insulin dose can easily be increased to 10-20 IU/hour or more if necessary. A clinical trial on the routine use of 20 IU/hour is in progress.
Introduction
Calcitonin was discovered as a hypocalcaemic hormone, but there is no evidence to suggest that it has a role in regulating plasma calcium levels in normal adults. It acts by inhibiting bone resorption,' 2 and it is therefore not surprising that its hypocalcaemic effect is best seen when bone resorption is increased -for example, in stages of rapid growth or in conditions such as Paget's disease or thyrotoxicosis.''
The effectiveness of calcitonin in treating Paget's disease is based on its ability to inhibit osteoclastic bone resorption.3-6 Since parathyroid hormone-stimulated increases in bone resorption in patients with chronic renal failure may lead to painful bone disease and fractures, the present study was begun on the
